Quantum Cyber N.V. (QUCY)
| Market Cap | 48.56M |
| Revenue (ttm) | 537,080 -39.9% |
| Net Income | -16.21M |
| EPS | -2.70 |
| Shares Out | 12.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,878,611 |
| Open | 2.461 |
| Previous Close | 3.000 |
| Day's Range | 2.460 - 4.930 |
| 52-Week Range | 0.300 - 4.930 |
| Beta | 0.43 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 31, 2026 |
About QUCY
Quantum Cyber N.V. engages in the marketing and sale of colorectal cancer screening product candidates. It also develops PancAlert, a stool-based screening test aimed at detecting pancreatic cancer. The company is headquartered in Mainz, Germany.
Financial Performance
In 2025, Quantum Cyber's revenue was $537,080, a decrease of -39.92% compared to the previous year's $893,991. Losses were -$16.21 million, -24.95% less than in 2024.
Financial StatementsNews
Quantum Cyber N.V. Launches quantum-cyber.ai Targeting Homeland Security, Autonomous Drone, & Quantum Technology Sectors
New Web Platform Positions Drone Warfare, Counter-UAS, EMP Shielding, Autonomous Demining, and Quantum Antenna Technology Highlights Featured as Trump Administration Seeks $55 Billion for Autonomous W...
Quantum Cyber Launches quantum-cyber.ai Targeting Homeland Security, Autonomous Drone, and Quantum Technology Sectors
WEST PALM BEACH, Fla, May 15, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (Nasdaq: QUCY) ("Quantum Cyber" or the "Company"), a company assembling an AI-powered, quantum-accelerated System-of-Systems a...
3 Penny Stocks to Watch Now, 5/14/26
Dreamland Limited ($TDIC), Quantum Cyber ($QUCY), and WORK Medical Technology Group ($WOK) are the three penny stocks to watch on May 14, according to TipRanks’ Penny Stock Screener tool. Penny…
Former Trump Administration VA Secretary Peter O'Rourke Sr. Joins Quantum Cyber's Board of Directors
Decorated U.S. Military Veteran, Former Acting Secretary of the U.S. Department of Veterans Affairs, and Nasdaq Board Chairman Brings Deep Defense, Government, and Capital Markets Expertise to Quantum...
Quantum Cyber secures exclusive autonomous drone license
Quantum Cyber (QUCY) announced the execution of an IP License Agreement with BP United, a developer of autonomous unmanned vehicle systems. “This is the first building block of what we…
Why Is Quantum Cyber Stock (QUCY) Up Today?
Quantum Cyber stock was up after the company secured rights to drones for military applications.
Quantum Cyber N.V. Secures Exclusive Autonomous Drone Platform as Trump Administration Seeks $55 Billion for Drone Warfare
Company Executes IP License Agreement with BP United Inc.; Quantum Antenna Technology Company Executes IP License Agreement with BP United Inc.; Quantum Antenna Technology
Quantum Cyber aligns strategy with Trump Admin’s National Cybersecurity Strategy
The company said, “On March 10, 2026, the White House released a sweeping National Cybersecurity Strategy document under the direction of President Donald Trump, articulating six foundational pillars ...
Quantum Cyber says shareholder David Lazar pre-funds additional tranche
The Company announce that David Lazar, a significant shareholder and strategic supporter, has pre-funded the second tranche in the amount of $3,000,000, pursuant to a previously announced private plac...
Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY
BERKELEY, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
BERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its fe...
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
BERKELEY, Calif. and MAINZ, Germany, Sept.
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
BERKELEY, Calif. and MAINZ, Germany, July 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
MYNZ Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and M...